42 completed, 10 terminated, 7 withdrawn, 4 unknown. 19 Phase 3, 12 Phase 4, 8 Not applicable, 8 Phase 2, 5 Phase 1.
Follow Fondaparinux: new trials by email Literature Review of Fondaparinux trials Research Report on Fondaparinux
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Hip Fracture Surgery Arterial and Venous Thrombotic Events Prevention rivaroxaban and ASA, Low-molecular weight heparin, Fondaparinux - Hip Fracture Surgery, Cardiovascular Prevention | Phase 3 | Not yet recruiting | McMaster University | 100 | 2025-12-01 | 2025-11-14 |
| Treatment With Aspirin Alone Versus Aspirin in Combination With Fondaparinux Before Early Coronary Assessment in Patients With Non-ST-Elevation Myocardial Infarction Aspirin, Fondaparinux Sodium - NSTEMI - Non-ST Segment Elevation Myocardial Infarction (MI), Acute Myocardial Infarction (AMI) | Phase 4 | Recruiting | University of Aarhus | 5076 | 2025-05-01 | 2026-05-04 |
| Endovenous Laser Ablation in Acute Thrombophlebitis of the Varicose Great Saphenous Vein Endovenous laser ablation, Fondaparinux Sodium - Superficial Vein Thrombosis, Endovenous Laser Ablation | Phase 4 | Completed | National Medical Research Center for Therapy and Preventive Medicine | 105 | 2021-08-16 | 2023-12-20 |
| Anticoagulation in Critically Ill Patients With COVID-19 (The IMPACT Trial) Enoxaparin sodium, Unfractionated heparin, Fondapariniux - COVID-19 | Phase 4 | Terminated | Weill Medical College of Cornell University | 14 | 2020-10-13 | 2023-09-21 |
| Increased Risk of VTE and Higher Hypercoagulability in Patients Recovered in ICU and in Medical Ward for COVID-19 thromboprophylaxis with low-molecular-weight heparin or fondaparinux - COVID-19 Disease, Thromboembolism, Venous | Completed | Quovadis Associazione | 90 | 2020-05-01 | 2020-09-17 | |
| Enhanced Platelet Inhibition in Critically Ill Patients With COVID-19 Tirofiban Injection, Clopidogrel, Acetylsalicylic acid - Pneumonia, Viral, Corona Virus Infection | Phase 2 | Completed | University of Milan | 5 | 2020-04-06 | 2020-04-29 |
| Safety of Fondaparinux as Post Partum Thromboprophylaxis Fondaparinux 2.5Mg/0.5Ml Inj Syr - Thromboembolism in the Puerperium | Phase 4 | Completed | National University of Malaysia | 60 | 2017-09-01 | 2020-06-26 |
| Hokusai Study in Pediatric Patients With Confirmed Venous Thromboembolism (VTE) Edoxaban, Standard of Care - Venous Thromboembolism (VTE), Pulmonary Embolism | Phase 3 | Completed | Daiichi Sankyo | 290 | 2017-03-27 | 2025-02-28 |
| Direct Oral Anticoagulants (DOACs) Versus LMWH +/- Warfarin for VTE in Cancer Rivaroxaban, Apixaban, Edoxaban - Cancer, Venous Thromboembolism | Not applicable | Completed | Alliance Foundation Trials, LLC. | 811 | 2016-12-13 | 2023-10-03 |
| Thromboprophylaxis of Venous Thromboembolism in Acutely-ill Medical Inpatients With Thrombocytopenia Fondaparinux - Medical Patient, Thrombocytopenia | Phase 4 | Terminated | G. d'Annunzio University | 7 | 2012-11-01 | 2021-07-21 |
| Prospective Study on the Treatment of Unsuspected Pulmonary Embolism in Cancer Patients Heparin, fondaparinux, vitamin-K antagonists, aspirin - Unsuspected Pulmonary Embolism | Completed | G. d'Annunzio University | 695 | 2012-11-01 | 2019-08-08 | |
| ARIXTRA® Adherence in SVT Patients. Fondaparinux - Thrombosis, Venous | Completed | GlaxoSmithKline | 1 | 2012-10-01 | 2015-03-27 | |
| Superficial Vein Thrombosis (SVT) Treated With Rivaroxaban Versus Fondaparinux Rivaroxaban, Fondaparinux - Superficial Vein Thrombosis | Phase 3 | Completed | GWT-TUD GmbH | 472 | 2012-04-01 | 2023-05-15 |
| Pilot Study Evaluating Alterations in Thrombogenicity and Platelet Reactivity Following Lower Extremity Arthroplasty Arixtra, Pneumatic compression stockings, Aspirin - Primary Total Hip and Knee Arthroplasty | Phase 4 | Completed | LifeBridge Health | 54 | 2012-04-01 | 2014-04-21 |
| Special Drug Use Investigation (Retrospective) for Arixtra® (Fondaparinux) Venous Thromboembolism Treatment (Over 100kg) Fondaparinux sodium - Ataxia | Completed | GlaxoSmithKline | 5 | 2012-03-01 | 2015-07-15 | |
| Safety and Pharmacokinetics Study of DU-176b Administered to Patients With Severe Renal Impairment Undergoing Orthopedic Surgery of The Lower Limbs 15mg DU-176b, 30mg DU-176b, Fondaparinux - Venous Thromboembolism | Phase 3 | Completed | Daiichi Sankyo Co., Ltd. | 80 | 2012-03-01 | 2019-03-05 |
| Special Drug Use Investigation for Arixtra® (Fondaparinux) Venous Thromboembolism Treatment Fondaparinux Sodium - Ataxia | Completed | GlaxoSmithKline | 200 | 2012-01-01 | 2015-07-15 | |
| Fondaparinux in Critically Ill Patients With Renal Failure Fondaparinux - Venous Thromboembolism | Phase 4 | Completed | Wayne State University | 32 | 2011-11-01 | 2015-06-19 |
| The Impact of Different Anticoagulant Therapy on Hemorrhage and Coagulation After Thoracic Surgery Fondaparinux, Nadroparin Calcium - Lung Neoplasms, Esophageal Neoplasms | Not applicable | Completed | Shanghai Zhongshan Hospital | 362 | 2011-01-01 | 2014-04-29 |
| "Pharmacokinetic Study of Fondaparinux in Inpatients With Renal Dysfunction" fondaparinux sodium injection - Renal Insufficiency | Phase 1 | Completed | Duke University | 9 | 2010-05-01 | 2014-09-01 |
Showing 20 of 65. Sign in to see all of them.
Venous Thrombosis (20) · Venous Thromboembolism (18) · Pulmonary Embolism (14) · Thromboembolism (7) · Thrombosis (7) · Renal Insufficiency (6) · Acute Coronary Syndrome (3) · COVID-19 (3) · Cardiovascular Diseases (3) · Hemorrhage (3) · Neoplasms (3) · Ataxia (2) · Myocardial Infarction (2) · Ovarian Neoplasms (2) · Thrombocytopenia (2)
GlaxoSmithKline (20) · Duke University (2) · G. d'Annunzio University (2) · University of Alabama at Birmingham (2) · Wayne State University (2) · Alliance Foundation Trials, LLC. (1) · Brigham and Women's Hospital (1) · Centre Hospitalier Universitaire de Saint Etienne (1) · Children's Hospital Los Angeles (1) · Daiichi Sankyo (1) · Daiichi Sankyo Co., Ltd. (1) · Eastern Virginia Medical School (1) · GWT-TUD GmbH (1) · Hamilton Health Sciences Corporation (1) · Indiana University (1)
United States (27) · Italy (8) · France (7) · Germany (7) · Canada (5) · Netherlands (5) · Japan (4) · Russia (4) · Spain (4) · Bulgaria (2) · Czechia (2) · Denmark (2) · Hungary (2) · Israel (2) · Malaysia (2)
Alessandro Squizzato, MD (1) · Bob L Lobo, Pharm.D. (1) · Boris Kobrinsky, M.D. (1) · Charles W Callender, MD (1) · Daniel R. Budman, MD (1) · Deborah Schrag, MD MPH (1) · Federico Germini, Doctor of Medicine (1) · Francesco Dentali, MD (1) · Francisco Robert, M.D. (1) · Goetz H Kloecker, MD, MSPH (1) · Guy Young, MD (1) · Igor S Yavelov, MD (1)
PMID 35244208, PMID 33502773, PMID 16537663, PMID 17723125, PMID 19825809, PMID 19854398, PMID 20124123, PMID 20860504, PMID 21319285, PMID 22925036, PMID 23216710, PMID 23821661, PMID 25653574, PMID 25975205, PMID 26448724, PMID 26699594, PMID 26973347, PMID 28219692, PMID 28279428, PMID 29169470, PMID 31116676, PMID 33368114, PMID 33942675, PMID 34172290, PMID 36413425, PMID 37266947, PMID 40945808
2008 (1), 2016 (1)